Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
Nur Akad SoyerRıdvan AliMehmet Turgutİbrahim Celallettin HaznedaroğluAsu Fergün Yılmazİsmet AydoğduAli PirVolkan KarakusGökhan ÖzgürCem KişFunda CeranGül İlhanMelda CömertMuzeyyen Aslaner Akİdris İnceIrfan YavasogluFüsun ÖzdemirkıranMehmet SonmezBirol GuvencGülsüm ÖzetEmin KayaFiliz VuralFahri ŞahinMahmut Töbüİsabel Raika DurusoyGuray SaydamPublished in: Turkish journal of medical sciences (2021)
We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.